Mylan, Ranbaxy Tell 3rd Circ. To Decertify Provigil Class
Mylan and Ranbaxy Laboratories urged the Third Circuit Monday to decertify a purchaser class accusing them of improperly inking pay-for-delay deals with Cephalon to keep generic versions of narcolepsy drug Provigil...To view the full article, register now.
Already a subscriber? Click here to view full article